Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Sanofi (NASDAQ:SNYGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $69.00.

Several equities research analysts have recently issued reports on the company. cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 29th. HSBC began coverage on Sanofi in a research note on Friday, July 14th. They issued a “buy” rating on the stock.

Read Our Latest Analysis on Sanofi

Institutional Trading of Sanofi

Several hedge funds and other institutional investors have recently modified their holdings of the business. Manhattan West Asset Management LLC lifted its holdings in shares of Sanofi by 20.0% during the 2nd quarter. Manhattan West Asset Management LLC now owns 34,728 shares of the company’s stock worth $1,872,000 after acquiring an additional 5,779 shares during the period. Rehmann Capital Advisory Group boosted its stake in shares of Sanofi by 13.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 10,518 shares of the company’s stock worth $567,000 after acquiring an additional 1,281 shares during the period. Osaic Holdings Inc. grew its stake in shares of Sanofi by 0.5% in the second quarter. Osaic Holdings Inc. now owns 257,012 shares of the company’s stock valued at $13,843,000 after acquiring an additional 1,306 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sanofi during the 2nd quarter worth $10,174,000. Finally, Orion Portfolio Solutions LLC increased its position in Sanofi by 964.9% in the 2nd quarter. Orion Portfolio Solutions LLC now owns 59,207 shares of the company’s stock valued at $3,191,000 after acquiring an additional 53,647 shares during the period. Institutional investors and hedge funds own 10.06% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $53.13 on Monday. The firm’s 50 day simple moving average is $52.91 and its 200-day simple moving average is $53.66. Sanofi has a 12 month low of $36.91 and a 12 month high of $57.82. The stock has a market capitalization of $134.14 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.60 and a beta of 0.56. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81.

Sanofi (NASDAQ:SNYGet Free Report) last issued its earnings results on Friday, July 28th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.07. Sanofi had a net margin of 16.07% and a return on equity of 27.94%. The company had revenue of $10.85 billion for the quarter, compared to the consensus estimate of $11.47 billion. Analysts expect that Sanofi will post 4.47 EPS for the current year.

About Sanofi

(Get Free Report

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.